Patients with triple-negative breast cancer (TNBC) and positive for human epidermal growth factor receptor 2 (HER2) who did not achieve pathological complete response (pCR) can have better survival after escalating adjuvant systemic therapies (8, 9). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.